Abstract
Summary
Evidence was presented that 9-E-6-MP is dealkylated by the human in amounts adequate to provide enough 6-MP to explain the effectiveness of this drug when it is administered to chronic granulocytic leukemia patients. 9-E-6-MP does not serve as substrate for xanthine oxidase, nor purine nucleoside phosphorylase. The possibility that the enzyme responsible for dealkylation is present in human bone marrow or neutro-phils is discussed.
Get full access to this article
View all access options for this article.